Showing posts with label vaccines. Show all posts
Showing posts with label vaccines. Show all posts

Saturday, 1 April 2017

Virus Hydrophobicity Can Help Purify Vaccines

We usually try to detect virus in our body, whenever we become ill. However, now with the development of medical field, some researchers have found out a new way for recognizing virus easily by looking at the external layers.

A virus has a very intricate structure. On surface area of all viruses, there are tiny knits of some proteins. And these are mainly responsible for the serious effect, created by virus after having an interaction with our cells or the favorable environment in the surrounding area. If there is any alteration in the series of protein, then the surface turns out to be hydrophobic. It means that the part may repel water, and as a result, a sticky substance is formed on the surface.

One of the members (Heldt) at chemical research department of Michigan University has stated something about the new innovations of the researchers. At present, many of the associates of this University are trying to have a concept on how the hydrophobicity on virus surface is to be applied for the improvement in the production of vaccines.

A comparison on a variety of results-

Heldt has also claimed that dealing with purification of vaccine means working on the interactions on surface. While there is a disintegration of all components, they may not be applied as a kind of remedy. In addition to it, identification and removal of viruses also have a direct relation with all these interactions. Such facts may be very useful to the experts to know the interactions of virus or germs with our cells. The good news is that Caryn Heldt as well as her associates has made a comparison of different computational and experimental techniques in order to know the chemistry of surface.

Hydrophobicity- How the researchers tried to identify it-

Hydrophobicity may be defined as a property, which is found in a molecule that seems to be repelled or resisted from water mass. As the hydrophobicity of virus is quite tough to determine, the associates of Heldt emphasize the use of hydrophobicity pattern. These experts have also evaluated the possible measurements of hydrophobicity on the basis of protein, present in virus. They have tested out the specimens with the application of two chromatography types. One is the blend of chemicals and another one is fluorescent tints, which cause the appearance of hydrophobic, gluey spots on surface of proteins. The main fact is that all measurements try to make out something, which is easily accessible.

According to Heldt, the capsid of virus is so big that it is intricate to do measurements. To clarify the issues, Heldt has explained that capsid refers to outer shell, which comprises sixty same types of proteins, such as, VP1, 2 or 3. Heldt along with other researchers has tested VP2 and its exposed areas. There is a good link among all the results. And it reveals that any virus, including PPV has hydrophobicity, which is easily assessable. After having a better understanding of these measurements, the researchers may be able to detect virus.

Saturday, 14 November 2015

Meningitis jab in Africa a stunning success


According to experts, a mass vaccination programme against meningitis A in Africa has been successful and over 220 million people were inoculated across 16 countries in the region’s meningitis belt. The meningitis belt stretches from sub-Saharan Africa to Gambia in the west to Ethiopia in the east. In 2013, across the total region, there were only four cases which had once faced thousands of death every year.

But World Health Organisation had warned that `huge epidemics’ would return if new vaccination programme does not tend to begin. The worst epidemic ever recorded was in 1996-97, where the disease had swept over the belt affecting more than a quarter of a million people leading to 25,000 deaths. The MenAfriVac, unlike other vaccines had been designed especially for Africa and a mass vaccination campaign had been started in 2010.

Dr Marie-Pierre Preziosi from World Health Organisation had stated that the disease had virtually disappeared from that part of the world. This mass immunisation programme was intended for individuals below 30 years but routine vaccination would be essential to make sure that the new-borns are not susceptible to the disease.

Game-Changer in Global Health with New Vaccine

Steve Davis, president and CEO of PATH that is an international non-profit organization which together with partners including the World Health Organization, the Bill and Melinda Gates Foundation and African government officials who have worked to research, develop and deliver a meningitis

A vaccine has commented that they are seeing a game-changer in global health with the new vaccine which has the ability to move toward elimination of the disease. Sub-Saharan African for atleast a century had the world’s highest rate of meningitis A, which is a severe infection of the thin lining of the brain and the spinal cord.

It is an airborne disease which tends to kill around 10% of the patients, usually infants, children and young adults. Among those who tend to survive, around 1 in 5 suffers severe brain damage or deafness. There are five kinds of meningitis where meningitis A is rare in other areas of the world, According to PATH, epidemics have taken place in Africa often about every eight to 12 years but it is not known why though environmental elements like dust drought, humidity tend to play a role.

Meningitis Vaccination Project – In Motion in 2001

In 1996, when an epidemic had spread through the region, around 250,000 people were affected and 25,000 had died. Davis informed that it was one of the things which parents feared the most, more than malaria, since if kids did not die, they would be neurologically damaged. The health ministers together with other African leaders, after the epidemics had approached WHO seeking help.

The Meningitis Vaccination Project had been set in motion in 2001 to create a vaccine suitable to prevent meningitis A which would be affordable for developing nations. Huge pharmaceutical companies in rich countries were not willing to take on what they envisaged as an unprofitable project, the manufacture of vaccine which would be sold below 50 cents a dose.

However, a pharmaceutical company in the developing world, the Serum Institute of India with support from foundations and international aid organizations, linked the effort and could produce a high volume of vaccine for under 50 cents for each inoculation according to Davis.


Wednesday, 19 August 2015

Ebola Vaccine Proves 100 Percent Effective in Trial


Development in Ebola Vaccine - 100% Effective

Development in Ebola vaccine has proved to be 100% effective in a trial which took place in Guinea and been named a `game changer’ by the World Health Organisation – WHO. Initially the results of the trial of the VSC-EBOV vaccine, created by the Public Health Agency of Canada and which had been developed by pharmaceutical company – Merck, were published in `The Lancet’.

 Director General of – WHO, Margaret Chan, had stated that ` this was an extremely promising development and the credit goes to the Guinean Government, the people living in the communities and our partners in this project. An effective vaccine will be another very important tool for both current and future Ebola outbreaks’.

The results so far has revealed that the said vaccine is effective 100 percent, however the trial is set to continue to attempt and establish conclusive evidence which could be utilised to protect the whole population through `herd immunity’.The trial had begun on March 23, 2015 with more than 4,000 close contacts of about 100 patients suffering from Ebola who had volunteered to get vaccinated.

Immediate Deployment of Vaccination – Helpful

The trial had been implemented with the use of the same `ring; method which had been used in eliminating smallpox and had been issued to each person who had come in contact with the infected person. It thus created a protective ring around them that prevented the virus from spreading around.

During the trial, around 50% of the rings were vaccinated instantly on identification of an infected person and 50% of the rings were vaccinated three weeks thereafter. This was done to enable the researchers to compare the results. In the group which had been vaccinated instantly, there was not a single one who went on to develop Ebola while those who had received the delayed vaccination, had only 16 who went on to develop Ebola.

 Immediate vaccination being proven to be completely effective, randomization has now ended. All individuals who were at risk of being affected of Ebola have been vaccinated immediately, since July 26. Besides immediate deployment of the vaccine in helping to terminate the epidemic, it will also minimise the time needed in collecting more conclusive evidence which will ultimately be essential to license the product.

Proven Effect of VSV-EBOV

One of the many organisations which have been implementing the trial, Medicins san Frontieres, has also been vaccinating all of its frontline workers. The medical director of the company, Bertrand Draguez has stated that with high efficacy, all the affected countries should immediately start and multiply ring vaccinations to break chains of transmission and vaccinate all frontline workers in order to protect them.

Around 28,000 people had been infected since the outbreak of Ebola epidemic in West Africa, in December 2013 where around 11,300 people had died of the ailment. Though the outbreak continues in Guinea, Liberia and Sierra Leone, the proven effectiveness of the VSV-EBOV vaccine has now provided hope that the spread of the dreadful disease would be arrested.

Guinea’s national coordinator for the Ebola had replied that this is Guinea’s gift to West Africa and the world. The thousands of volunteers from Conakry and other areas of Lower Guinea as well as the many Guinean doctors, data managers and community mobilisers have made their contribution in finding a line of defence against a terrible disease – EBOLA

Sunday, 25 December 2011

Vaccines for children are safe, say Canadian health authorities

While health authorities released studies that show that there is no link between thimerosal and autism, critics claim that thimerosal, a mercury-based preservative used to prevent bacterial growth in vials multi-dose vaccine, greatly increases the risk of autism, a mental health disorder poorly understood, which limits the ability of a person to interact with the world around him.

But a spokesman for the Public Health Service of Canada says there is nothing to worry about. According to Julian Beltrame, head of Media Relations with the Public Health Service of Canada: "Most of the vaccines used in Canada do not contain this ingredient."

According to the Public Health Service, none of the usual childhood vaccine contains thimerosal, with the exception of certain vaccines against hepatitis B. Some vaccines against influenza also contain this ingredient, however, manufacturers are preparing a thimerosal-free formula.

Mr Beltrame to state "We are in the process of elimination, not because of scientific concerns, but because of public perception. For us, there is no credible study showing that there is any link with autism or other conditions. "

For cons, the opponent says its studies show that exposure to thimerosal through immunization represents "a significant risk factor" in the development of neurological disorders.

In any case, such as thimerosal is not present in most vaccines used here, a document from the National Advisory Committee on Immunization states that "the level of mercury exposure of Canadian children through vaccines, even in areas where there is a program of routine immunization against hepatitis B, is well below the limits traditionally acceptable and admissible. "

Moreover, public health officials insist that the costs associated with non-vaccination of children outweigh the risks. "Parents who do not vaccinate their children take risks to their health, but also for the health of those suffering from allergies or diseases against which there is no immunization and those who were immunized but who have not acquired immunity, "wrote Chief of Public Health of Canada, Dr. David Butler-Jones, in an article for the Toronto Star.

This article, entitled "Myths about vaccines and their dangers," praised the effects of routine vaccination on the health of Canadians and provides examples where the non-vaccination led to disease outbreaks.

"It may be because the vaccine was so effective that many people think they are no longer needed. As against these diseases can return if we let our guard. Between 1993 and 1997, 5,000 deaths were caused by diphtheria in the former Soviet Union after the failure of organized immunization. In 2003, campaigns to eradicate polio, which have since resumed, were halted in Nigeria because of false information about the oral polio vaccine. Polio has reappeared in a growing number of sub-Saharan Africa and has recently spread from Sudan to Yemen and Indonesia. Campaigns against whooping cough vaccine in Britain, which were based on false data about the risk of vaccines, have resulted in immunization rates have fallen and caused other outbreaks that caused more deaths and brain damage in children than we dare imagine, "wrote Mr. Butler-Jones.

"These are the facts. It is a needless tragedy when a child dies or becomes disabled because it has not been vaccinated. "

Sunday, 25 September 2011


Closely associated with the Lac St. Jean where it abounds, the word "blueberry" - or "beluet" or "cornflower" - has come to mean, a little ironically, its inhabitants, who are said to have the same characteristics as the berries of the plant that means: half sweet, half sour, slightly pasty, but with a fabulous creative potential ...

For the French, the word is one of the popular names of another plant, the cornflower blue, which can cause some confusion since the two plants have a therapeutic effect. Hence the importance of identifying plants by their Latin name, is not it? Vaccinium angustifolium, Vaccinium myrtilloides or so.

It is believed that the name comes from medieval Latin vaccinus, vaccines, which means "cow", but no explanation is given about the reasons for this association. Is it because in Europe, blueberries have been used in pastures for cows? In any case, certainly in our blueberry fields to us, were much more likely to encounter a brown bear, gender and hypoglycemic bad mood, an ox under placid. To monitor closely.